The short answer
BPC-157 is supplied lyophilised and is most stable dry, cold and dark. Its proline content confers enzymatic resistance and it lacks cysteine and methionine, so the common chemical degradation routes do not apply, leaving hydrolysis and physical handling as the practical concerns.
Key facts
- Supplied as
- White lyophilised powder
- Enzymatic resistance
- High (four prolines)
- Disulfide risk
- None (no cysteine)
- Oxidation risk
- Low (no methionine)
- Main chemical route
- Hydrolysis
- Physical concern
- Adsorption; freeze-thaw damage
Why the stability claim does not change storage
This is the point most likely to be got wrong. BPC-157 is described as stable in gastric juice, which is a claim about enzymatic and acidic resistance. Storage guidance addresses chemical hydrolysis, which proceeds without any enzyme and is a function of water, temperature and time. Proline protects against the first and does nothing about the second.
What the composition rules out
No cysteine, so no disulfide formation or scrambling and no reducing agent required. No methionine, so no thioether oxidation and no +16 Da satellite on a mass spectrum. Between them these account for most of what goes wrong with research peptides, and neither applies here.
Research material referenced
BPC-157 5mg, third-party HPLC tested
What remains
Backbone hydrolysis, slowed but not prevented by proline. And an aspartate-glycine sequence at positions 11 to 13, which in some peptides is a site for aspartate-related rearrangement. This is useful to know, though it is a slower process than the routes that dominate elsewhere.
Reconstitution
Introduce diluent gently down the vial wall rather than onto the powder, and swirl rather than shake. Foaming indicates an air-liquid interface has formed, which is where peptides unfold before aggregating. BPC-157 is hydrophilic and dissolves readily, so vigorous agitation is never needed.
After reconstitution
Aliquot into single-use volumes. Each freeze-thaw cycle concentrates solutes at the advancing ice boundary and creates fresh interfaces, and neither is prevented by the peptide's enzymatic robustness. Chemical and physical stability are separate properties, and BPC-157 is strong on the first and ordinary on the second.
Signs of a problem
Cloudiness, particulates or discolouration in a reconstituted solution mean the material should not be relied on for a measurement. Difficulty dissolving at a concentration that previously worked suggests aggregation, which for a peptide this soluble would be a meaningful signal.
Frequently asked questions
If BPC-157 is stable, why store it cold?
The stability claim concerns enzymatic and acidic degradation. Chemical hydrolysis needs no enzyme and is what cold, dry storage addresses.
Does it need a reducing agent?
No. There is no cysteine in the sequence.
Why avoid shaking?
Shaking creates an air-liquid interface where peptides unfold and aggregate. Foam is the visible evidence.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedSikiric P et al. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- PubMedStability of protein pharmaceuticals: an update. Pharm Res (PMID 20143256)pubmed.ncbi.nlm.nih.gov
- PubMedNail SL et al., Fundamentals of freeze-drying. Pharm Biotechnol 2002 (PMID 12189727)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- BPC-157 Mechanism: Why It Is Described as Multi-PathwayReported effects span angiogenic signalling, growth-factor interactions and nitric oxide pathways. Why no single defining mechanism has emerged.
- BPC-157 and Blood VesselsVascular effects recur across the BPC-157 literature and offer the most plausible common thread linking its reported activity in different tissues.
- Tendon and Ligament ModelsKrivic on Achilles detachment and Cerovecki on ligament healing, both in the Journal of Orthopaedic Research. What rat models can and cannot establish.
- Growth Factor Signalling in the BPC-157 LiteratureReported interactions with growth-factor systems are part of the multi-pathway description. What that means when no receptor for the peptide is known.
- BPC-157 Studied Effects, Sorted by EvidenceGastrointestinal, tendon, ligament and vascular models, plus clinical development as PL-14736 and a Phase 2 recruiting now. Ranked by how well established.